A clinical study on single-dose intravenous iron therapy’s impact on hemoglobin and its outcomes in hospitalized chronic kidney disease patients

Anemia is a common complication in Chronic Kidney Disease (CKD) due to reduced erythropoietin production and iron deficiency, leading to poor patient outcomes. Intravenous (IV) iron therapy is preferred over oral supplements for its efficacy in rapidly improving hemoglobin levels and replenishing iron stores. Single-dose IV iron formulations like Ferric Carboxymaltose offer a convenient and effective option for anemia management in Chronic Kidney Disease (CKD) patients. Study on single-dose intravenous iron therapy’s impact on hemoglobin and its outcomes in hospitalized chronic kidney disease patients. A cross-sectional study was conducted on 200 hospitalized Chronic Kidney Disease (CKD) patients receiving single-dose IV iron therapy (Ferric Carboxymaltose, Iron Sucrose, or Monoferric). Outcomes including hemoglobin improvement, iron parameters, adverse events, and cost-effectiveness were analyzed pre- and post-treatment. The majority of patients (59%) were over 50 years old, with males accounting for 55% of the study group. The most prevalent comorbidities were Hypertension (91.5%) and type 2 diabetes (51%). The average Body Mass Index (BMI) reduced from 22.8 to 21.2 after the intervention. The most commonly provided iron formulation was Ferric Carboxymaltose (69.5%), followed by iron sucrose (16.5%) and Monoferric (14%). Hemoglobin levels rose by an average of 2.3 units in 51.5% of patients, with a mean time to target of 5.1 days. Ferritin levels increased by 41.4% after therapy, whereas TIBC and transferrin saturation remained stable. Hypertension was the most common side effect, with 74 cases documented (23 mild, 43 moderate, and 8 severe). The study found that Single-Dose Intravenous Iron therapy increases hemoglobin levels and Iron parameters in CKD patients, with Ferric Carboxymaltose being the most effective formulation. The medication also reduced post-hemodialysis BMI and was cost-effective for anemia management. The most common comorbidity was hypertension, and while there were some adverse events, they were largely controlled. Overall, Intravenous Iron therapy reduced anemia and its associated hazards, leading to better patient outcomes in Chronic Kidney Disease (CKD) care.